Market openNon-fractional
Aurinia Pharmaceuticals/AUPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.
Ticker
AUPH
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Edmonton, Canada
Employees
300
Website
www.auriniapharma.com
AUPH Metrics
BasicAdvanced
$780M
Market cap
-
P/E ratio
-$0.44
EPS
1.42
Beta
-
Dividend rate
Price and volume
Market cap
$780M
Beta
1.42
Financial strength
Current ratio
5.605
Quick ratio
4.902
Long term debt to equity
20.534
Total debt to equity
24.629
Interest coverage (TTM)
-15.47%
Management effectiveness
Return on assets (TTM)
-8.10%
Return on equity (TTM)
-16.69%
Valuation
Price to revenue (TTM)
4.103
Price to book
2.18
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-38.107
Growth
Revenue change (TTM)
30.37%
Earnings per share change (TTM)
-35.98%
3-year revenue growth
55.40%
3-year earnings per share growth
-25.17%
What the Analysts think about AUPH
Analyst Ratings
Majority rating from 6 analysts.
AUPH Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$50M
11.78%
Net income
-$11M
-60.07%
Profit margin
-21.27%
-64.28%
AUPH Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.09
-$0.19
-$0.07
-
Expected
-$0.18
-$0.17
-$0.16
-$0.14
$0.01
Surprise
-56.36%
-46.15%
16.33%
-48.78%
-
AUPH News
AllArticlesVideos
Aurinia to Participate in Upcoming Investor Healthcare Conferences
Business Wire·3 days ago
Aurinia Announces 2024 Annual General Meeting Results
Business Wire·3 weeks ago
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aurinia Pharmaceuticals stock?
Aurinia Pharmaceuticals (AUPH) has a market cap of $780M as of July 05, 2024.
What is the P/E ratio for Aurinia Pharmaceuticals stock?
The price to earnings (P/E) ratio for Aurinia Pharmaceuticals (AUPH) stock is 0 as of July 05, 2024.
Does Aurinia Pharmaceuticals stock pay dividends?
No, Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Aurinia Pharmaceuticals dividend payment date?
Aurinia Pharmaceuticals (AUPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals (AUPH) has a beta rating of 1.42. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Aurinia Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.